Last reviewed · How we verify
NCT05282914
A Study to Compare PK, PD and Safety of UI058 and UIC202004 in Healthy Subjects
Phase 1 trial testing administration of UI058 in GERD in 41 participants. Completed in 1 September 2021.
14 April 2021
Quick facts
| Lead sponsor | Korea United Pharm. Inc. |
|---|---|
| Phase | Phase 1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 41 |
| Start date | 3 February 2021 |
| Primary completion | 14 April 2021 |
| Estimated completion | 1 September 2021 |
| Sites | 1 location across South Korea |
Drugs / interventions tested
- administration of UI058 — full drug profile →
- administration of UIC202004 — full drug profile →
Conditions studied
- GERD — all drugs for GERD →
Sponsor
Korea United Pharm. Inc. — full company profile →
Who can join
Adults 19 to 55, any sex, with GERD. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
A Study to compare pharmacokinetics, pharmacodynamics and safety of UI058 and UIC202004 in healthy subjects
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05282914
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for GERD
Currently open trials in the same condition.
- NCT06953986 — A Randomized, Three-Arm Study Comparing Vonaprazan 10 mg, Vonaprazan 20 mg, and Esomeprazole 40 mg for the Healing of LA · NA · recruiting
- NCT07421011 — Pharmacokinetics, Bioequivalence, and Safety Study of Trimedat® 76,95 mg Orally Disintegrating Tablets and Trimedat® 100 · Phase 1 · recruiting
- NCT07268820 — Heartburn, Gastroesophageal Reflux Disease · Phase 4 · recruiting
- NCT06955520 — Vonaprazan Versus Esomeprazole for Healing of LA Grade B or Higher Esophagitis After POEM · NA · recruiting
- NCT06641375 — Anti-Reflux Endoscopic Therapy Using Argon Plasma Coagulation (AREA) in Gastroesophageal Reflux Disease (GERD) Patients: · NA · recruiting
Other Korea United Pharm. Inc. trials
Trials by the same sponsor.
- NCT07162441 — A Two-arm, Open-label, Single-sequence, Multiple-dose, Cross-over Study to Evaluate the Pharmacokinetic Interaction and · Phase 1 · recruiting
- NCT07110740 — Bioequivalence Study Between UI009 and UIC202005 in Healthy Subjects · Phase 1 · completed
- NCT06393881 — A Study to Compare and Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of UI059 and UIC202201 · Phase 1 · not yet recruiting
- NCT06141577 — A Study to Compare Pharmacokinetics, Pharmacodynamics and Safety of UI059 and UIC202201 in Healthy Subjects · Phase 1 · completed
- NCT06141590 — A Clinical Study to Evaluate the Safety and the Pharmacokinetics of UI068 in Healthy Adult Volunteers Under Fed Conditio · Phase 1 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05282914 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Korea United Pharm. Inc.
- Last refreshed: 3 July 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05282914.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing